Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Director | April 01, 2026 | April 07, 2026 |
| OptiNose, Inc.OPTN · Entity 79464 | Chief Financial Officer | March 16, 2022 | March 17, 2022 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Chief Financial Officer | June 01, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date April 01, 2026 · Filed April 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,751 |
Reported balance
After 2026-04-01 transaction · row 1
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 32,751 · Balance 32,751 F1: All of the restricted stock will vest on April 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the restricted stock will vest on April 1, 2027.
OptiNose, Inc.
Report date March 16, 2022 · Filed March 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 141,726 |
Reported balance
After 2022-03-16 transaction · row 1
1 source rowRow 1 · 2022-03-16 · Sale · Disposed 4,617 · Balance 141,726 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Syndax Pharmaceuticals Inc
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 139,252 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Sale · Disposed 1,177 · Balance 139,252 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 2, 2026 20:30 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 1,177 | $18.99 | $22,351.23 |
DisclosureSEC source: 0001193125-26-253603 · ownership.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,252 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 01, 2026 Filed Apr 7, 2026 12:47 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 32,751 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-015456 · ownership.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,751 F1 · shares: All of the restricted stock will vest on April 1, 2027. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 13:59 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 3,410 | $21.03 | $71,705.48 |
DisclosureSEC source: 0001193125-26-043813 · ownership.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,429 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 22:53 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 2,082 | $20.62 | $42,930.84 |
DisclosureSEC source: 0001193125-26-041497 · ownership.xml · nonDerivative · entry 4 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,839 F4 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 22:53 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 118,000 | $20.43 Strike: $20.43 | $2,410,740.00 |
DisclosureSEC source: 0001193125-26-041497 · ownership.xml · derivative · entry 5 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2036-02-04 F5 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 22:53 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 30,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-041497 · ownership.xml · nonDerivative · entry 3 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,921 F3 · shares: Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 22:53 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 21,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-041497 · ownership.xml · nonDerivative · entry 2 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,171 F2 · shares: Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested. Read SEC document |
| January 30, 2026 Filed Feb 6, 2026 22:53 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 1,219 | $8.48 | $10,337.12 |
DisclosureSEC source: 0001193125-26-041497 · ownership.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,671 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,219 shares by the Reporting Person on 1/30/2026 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| December 01, 2025 Filed Dec 1, 2025 21:30 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GiftCommon Stock | 1,224 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-303941 · ownership.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,452 Read SEC document |
| July 31, 2025 Filed Aug 7, 2025 21:30 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 1,226 | $8.43 | $10,335.18 |
DisclosureSEC source: 0000950170-25-105258 · ownership.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,676 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,226 shares by the Reporting Person on 07/31/2025 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:30 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 1,296 | $9.29 | $12,033.36 |
DisclosureSEC source: 0000950170-25-096948 · ownership.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,450 F1 · price: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 19, 2025 Filed May 19, 2025 20:04 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | PurchaseCommon Stock | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074304 · ownership.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,746 F1 · price: The purchase prices ranged from $8.8465 to $9.2825. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 3,777 | $15.50 | $58,558.61 |
DisclosureSEC source: 0000950170-25-019005 · ownership.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,746 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 110,500 | $14.65 Strike: $14.65 | $1,618,825.00 |
DisclosureSEC source: 0000950170-25-016389 · ownership.xml · derivative · entry 3 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,500 Underlying: Common Stock · 110,500 shares Expires 2035-02-05 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 23,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-016389 · ownership.xml · nonDerivative · entry 2 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,523 F2 · shares: Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:44 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 18,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-016389 · ownership.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,123 F1 · shares: Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 13:26 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | PurchaseCommon Stock | 1,250 | $20.03 | $25,037.25 |
DisclosureSEC source: 0001562180-24-005118 · primarydocument.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,623 Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 21:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 70,000 | $22.28 Strike: $22.28 | $1,559,600.00 |
DisclosureSEC source: 0001562180-24-001222 · primarydocument.xml · derivative · entry 5 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-02-07 F5 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 21:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 11,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001222 · primarydocument.xml · nonDerivative · entry 4 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,373 F4 · shares: Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 21:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001222 · primarydocument.xml · nonDerivative · entry 3 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,673 F3 · shares: Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested. Read SEC document |
| January 31, 2024 Filed Feb 9, 2024 21:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 1,183 | $17.42 | $20,607.86 |
DisclosureSEC source: 0001562180-24-001222 · primarydocument.xml · nonDerivative · entry 2 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,673 F2 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,183 shares by the Reporting Person on 01/31/2024 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 31, 2023 Filed Feb 9, 2024 21:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 862 | $18.12 | $15,619.44 |
DisclosureSEC source: 0001562180-24-001222 · primarydocument.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,490 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 862 shares by the Reporting Person on 07/31/2023 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 20:20 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 577 | $22.31 | $12,872.87 |
DisclosureSEC source: 0001562180-23-005152 · primarydocument.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,628 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:00 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 110,000 | $28.55 Strike: $28.55 | $3,140,500.00 |
DisclosureSEC source: 0001562180-23-000953 · primarydocument.xml · derivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2033-02-02 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:12 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 230,000 | $15.60 Strike: $15.60 | $3,588,000.00 |
DisclosureSEC source: 0001562180-22-005117 · primarydocument.xml · derivative · entry 2 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2032-06-13 F2 · derivative.exercise_date: Twenty five percent (25%) of the total number of shares underlying the option shall vest on June 13, 2023, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:12 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 3,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005117 · primarydocument.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,205 F1 · shares: Award of Restricted Stock Units that vest 50% of the shares on June 13, 2023 and the remaining 50% of the shares on June 13, 2024. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 17:23 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 4,617 | $2.11 | $9,741.87 |
DisclosureSEC source: 0001494650-22-000029 · wf-form4_164753781398908.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,726 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 21:02 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 66,185 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001494650-22-000006 · wf-form4_164202134380026.xml · derivative · entry 3 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,185 Underlying: Common Stock · 66,185 shares Expires 2026-01-11 F3 · shares: Represents the maximum number of options eligible to vest during the 4-year vesting period subject to the achievement of certain performance-based objectives relating to the trading price of OptiNose, Inc. common stock. If the minimum performance criteria relating to the trading price of OptiNose, Inc. common stock is not achieved, then none of the options will be eligible to vest. F4 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period, commencing on January 11, 2022, subject to the achievement of certain performance-based objectives relating to the trading price of OptiNose, Inc. common stock and continued service with the Issuer. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 21:02 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 85,095 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001494650-22-000006 · wf-form4_164202134380026.xml · derivative · entry 2 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,095 Underlying: Common Stock · 85,095 shares Expires 2032-01-11 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on January 11, 2022. Twenty-five percent (25%) of the option vests and becomes exercisable on January 11, 2023, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 21:02 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 56,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-22-000006 · wf-form4_164202134380026.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,343 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on January 11, 2023, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 14:27 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 580 | $1.64 | $951.20 |
DisclosureSEC source: 0001494650-21-000155 · wf-form4_163975122697686.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,613 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 16, 2021 Filed Sep 17, 2021 17:53 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 578 | $2.79 | $1,612.04 |
DisclosureSEC source: 0001494650-21-000108 · wf-form4_163190116827344.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,193 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 22:35 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 576 | $3.73 | $2,148.48 |
DisclosureSEC source: 0001494650-21-000076 · wf-form4_162396931494948.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,771 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:11 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 2,304 | $3.92 | $9,031.68 |
DisclosureSEC source: 0001494650-21-000041 · wf-form4_161601907384985.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,347 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:19 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $3.51 Strike: $3.51 | $280,800.00 |
DisclosureSEC source: 0001494650-21-000018 · wf-form4_161524193371157.xml · derivative · entry 2 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-03-04 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on March 4, 2021. Twenty-five percent (25%) of the option vests and becomes exercisable on March 4, 2022, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:19 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 53,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-21-000018 · wf-form4_161524193371157.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,084 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on March 15, 2022, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| September 23, 2020 Filed Sep 23, 2020 20:47 UTC | OptiNose, Inc. OPTN · Entity 79464 | PurchaseCommon Stock | 2,500 | $3.90 | $9,742.50 |
DisclosureSEC source: 0001494650-20-000125 · wf-form4_160089405254597.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,751 F1 · balance_after: Includes 490 shares acquired under the Company's employee stock purchase plan on June 30, 2020 at a per share purchase price of $7.34. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 11:06 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantRestricted Stock Units · Derivative | 30,567 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001494650-20-000031 · wf-form4_158375195126807.xml · derivative · entry 2 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,567 Underlying: Common Stock · 30,567 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of OptiNose, Inc. Twenty-five percent (25%) of the RSUs vest on March 6, 2021, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of OptiNose, Inc. Twenty-five percent (25%) of the RSUs vest on March 6, 2021, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 11:06 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 45,850 | $5.41 Strike: $5.41 | $248,048.50 |
DisclosureSEC source: 0001494650-20-000031 · wf-form4_158375195126807.xml · derivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,850 Underlying: Common Stock · 45,850 shares Expires 2030-03-06 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on March 6, 2020. Twenty-five percent (25%) of the option vests and becomes exercisable on March 6, 2021, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| March 06, 2020 Filed Mar 17, 2021 22:04 UTC Amendment | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 45,850 | $5.41 Strike: $5.41 | $248,048.50 |
DisclosureSEC source: 0001494650-21-000032 · wf-form4a_161601863167747.xml · derivative · entry 2 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,850 Underlying: Common Stock · 45,850 shares Expires 2030-03-06 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on March 6, 2020. Twenty-five percent (25%) of the option vests and becomes exercisable on March 6, 2021, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| March 06, 2020 Filed Mar 17, 2021 22:04 UTC Amendment | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 30,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-21-000032 · wf-form4a_161601863167747.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,328 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on March 15, 2021, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| December 31, 2019 Filed Jan 16, 2020 21:11 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 2,695 | $6.13 | $16,520.35 |
DisclosureSEC source: 0001494650-20-000002 · wf-form5_157920905942139.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,761 F1 · kind: Shares acquired under the Optinose, Inc. 2017 Employee Stock Purchase Plan on December 31, 2019 in a transaction exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 28, 2019 Filed Jul 9, 2019 11:30 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 941 | $5.64 | $5,307.24 |
DisclosureSEC source: 0001494650-19-000067 · wf-form4_156267179853617.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,066 F1 · kind: Shares acquired under the OptiNose, Inc. 2017 Employee Stock Purchase Plan on June 28, 2019 in a transaction exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 28, 2019 Filed Mar 6, 2019 23:27 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 82,500 | $0.00 Strike: $7.42 | $0.00 |
DisclosureSEC source: 0001494650-19-000027 · wf-form4_155191483222043.xml · derivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2029-02-28 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 28, 2019. Twenty-five percent (25%) of the option vests and becomes exercisable on February 28, 2020, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| June 29, 2018 Filed Jan 8, 2019 21:54 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 3,125 | $13.60 | $42,500.00 |
DisclosureSEC source: 0001494650-19-000010 · wf-form5_154698442574019.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · kind: Shares acquired under the Optinose, Inc. 2017 Employee Stock Purchase Plan on June 29, 2018 in a transaction exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 16:41 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 72,197 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-17-062326 · a4.xml · derivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,197 Underlying: Common Stock · 72,197 shares Expires 2027-10-11 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on October 12, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on October 12, 2018, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.